Detalles de la búsqueda
1.
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
Lancet
; 403(10437): 1649-1659, 2024 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38582092
2.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35665782
3.
Characterization of HER2-low breast cancer in young women with germline BRCA1/2 pathogenetic variants: Results of a large international retrospective cohort study.
Cancer
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38752572
4.
CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.
Oncologist
; 29(5): e622-e634, 2024 May 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175669
5.
Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial.
Eur J Nucl Med Mol Imaging
; 2024 Apr 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38587643
6.
Optimising of axillary therapy in breast cancer: lessons from the past to plan for a better future.
Radiol Med
; 129(2): 315-327, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37922004
7.
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
Lancet Oncol
; 24(3): 273-285, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36858723
8.
Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
Breast Cancer Res
; 25(1): 2, 2023 01 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36631725
9.
Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
Cancer
; 129(12): 1836-1845, 2023 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36951169
10.
Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study.
Cancer Immunol Immunother
; 72(6): 1709-1723, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-36625938
11.
Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer.
Br J Cancer
; 127(10): 1787-1792, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35995934
12.
Biomarkers of immunotherapy response in breast cancer beyond PD-L1.
Breast Cancer Res Treat
; 191(1): 39-49, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34676466
13.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study.
Future Oncol
; 18(33): 3677-3688, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36300423
14.
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer.
Future Oncol
; 18(32): 3563-3572, 2022 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-36382554
15.
SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.
Future Oncol
; 2022 Oct 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36200668
16.
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial.
Lancet Oncol
; 22(6): 858-871, 2021 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-34019819
17.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Lancet Oncol
; 22(4): 489-498, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33794206
18.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33460574
19.
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Breast Cancer Res
; 23(1): 8, 2021 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33451345
20.
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer.
Breast Cancer Res
; 23(1): 42, 2021 03 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-33785053